Ateyatallah Aljuhani, Mohamed S. Nafie, Nader R. Albujuq, Mosa Alsehli, Sanaa K. Bardaweel, Khaled M. Darwish, Shaya Y. Alraqa, Mohamed Reda Aouad and Nadjet Rezki
RSC Adv., 2025,15, 3570-3591
Abstract
New benzothiazole-1,2,3-triazole hybrids-based hydrazone/thiosemicarbazone derivatives exhibited potent EGFR inhibitors with cytotoxicity against breast cancer.
Virginia Pontecorvi, Andrea Angeli, Luigi Cutarella, Mattia Mori, Daniela Secci, Michele Coluccia, Simone Carradori, Anna Troiani, Federico Pepi, Chiara Salvitti, Alessia Di Noi, Mattia Spano, Francesca Arrighi, Elena De Falco, Antonella Bordin, Emanuela Berrino, Arianna Granese, Paola Chimenti, Paolo Guglielmi and Claudiu T. Supuran
RSC Med. Chem., 2025,16, 3603-3621
Abstract
Development of the novel coumalic acid-based selective hCA IX and XII inhibitors.
Ahmed A. Al-Karmalawy, Ayman Abo Elmaaty, Aya Yaseen Mahmood Alabdali, Saad Shaaban, Arwa Omar Al Khatib, Magda H. Abdellattif, Alaa Abu Alnjaa, Marwa Sharaky, Wagdy M. Eldehna and Ahmed A. Gaber
New J. Chem., 2025,49, 6025-6037
Abstract
New pyrazolopyrimidine analogues as multi-target directed EGFR/STAT3 downregulatory candidates endowed with apoptotic potential.
Samvel N. Sirakanyan, Domenico Spinelli, Athina Geronikaki, Elmira K. Hakobyan, Anti Petrou, Victor G. Kartsev, Hasmik A. Yegoryan, Ervand G. Paronikyan, Luca Zuppiroli, Hasmik V. Jughetsyan, Ruzanna G. Paronikyan, Tatevik A. Arakelyan and Anush A. Hovakimyan
RSC Adv., 2024,14, 32922-32943
Abstract
Herein, we describe the synthesis and biological activity of new hybrids linked to 1,2,3- and 1,2,4-triazole units.
Xiangying Li, Yuanyuan Liu, Wen Shao, Deling Jiang, Xupeng Huang, Zihe Rao, Wei Peng and Yuying Fang
RSC Med. Chem., 2026,17, 1066-1082
Abstract
Integrated virtual and biological screening guided the design and synthesis of 50 novel pyrimido[1,2-a]imidazole derivatives, leading to the discovery of potent Pks13-TE inhibitor 34 (IC50 = 0.23 μM).